REVA Medical Inc. Expands CE Mark Trial to Australia and New Zealand
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SAN DIEGO, June 27, 2013 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") is pleased to announce that it is now enrolling patients with its ReZolve®2 bioresorbable scaffold at multiple clinical sites in Australia and New Zealand. This is in addition to previously announced sites in Brazil, Germany and Poland, which began enrolling patients earlier this year. Up to 125 patients are expected to be enrolled in REVA's clinical trial to provide the data necessary to apply for European CE Marking.
Help employers find you! Check out all the jobs and post your resume.
SAN DIEGO, June 27, 2013 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") is pleased to announce that it is now enrolling patients with its ReZolve®2 bioresorbable scaffold at multiple clinical sites in Australia and New Zealand. This is in addition to previously announced sites in Brazil, Germany and Poland, which began enrolling patients earlier this year. Up to 125 patients are expected to be enrolled in REVA's clinical trial to provide the data necessary to apply for European CE Marking.
Help employers find you! Check out all the jobs and post your resume.